Cover Image
市場調查報告書

黑素瘤(melanoma)治療藥市場預測:主要經營者的市場機會

Melanoma Drugs Market Forecast 2014-2024: Opportunities for Leading Companies

出版商 Visiongain Ltd 商品編碼 318037
出版日期 內容資訊 英文 215 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
黑素瘤(melanoma)治療藥市場預測:主要經營者的市場機會 Melanoma Drugs Market Forecast 2014-2024: Opportunities for Leading Companies
出版日期: 2014年11月04日 內容資訊: 英文 215 Pages
簡介

本報告提供黑素瘤(melanoma)的各種治療藥市場相關調查,提供您市場現狀及各種趨勢,市場規模及市場佔有率的變化與預測,依地區/主要國家·藥物類別彙整主要經營者,主要藥物,開發平台趨勢等資訊。

第1章 報告概要

第2章 簡介:癌症·黑色素瘤·黑色素瘤的治療方法

  • 癌症:生理學·原因·影響
    • 無秩序的增生
    • 脫分化
    • 侵入性與轉移
    • 癌症的原因
  • 黑色素瘤:概要
    • 黑色素瘤的原因
    • 黑色素瘤的症狀及出現
  • 黑色素瘤的分期
    • 早期
    • 中期
    • 晚期
  • 黑色素瘤的發病率和其預測:全球趨勢
  • 黑色素瘤的治療手術
  • 黑色素瘤治療上放射治療的實施
  • 黑色素瘤的藥物治療
    • 傳統的化療
    • 免疫療法
      • 單株抗體 (MAb)
      • 癌症疫苗
      • 非特異性免疫療法
  • 市場定義

第3章 全球黑色素瘤治療藥市場預測

  • 全球黑色素瘤治療藥:市場概要
    • 全球黑色素瘤治療藥市場分類
  • 全球黑色素瘤市場現在
    • 免疫療法藥及標靶治療的市場上的優勢
  • 全球黑色素瘤治療藥:市場預測
    • 推動和預測的部門成長
    • 全球黑色素瘤治療藥市場:各部門佔有率的變化預測

第4章 黑色素瘤激化酵素抑制劑:全球市場分析與預測

  • 全球黑色素瘤激化酵素抑制劑市場的現況
    • 黑色素瘤激化酵素抑制劑:全球市場的預測
    • 黑色素瘤激化酵素抑制劑:主要藥物的佔有率的變化預測
  • Dabrafenib (Tafinlar): GlaxoSmithKline
    • Dabrafenib (Tafinlar):銷售額預測
  • Trametinib (Mekinist):GlaxoSmithKline
    • Trametinib (Mekinist):銷售額預測
  • Vemurafenib (Zelboraf):Roche/Genentech/內外/第1三共
    • Vemurafenib (Zelboraf):過去的銷售情況
    • Vemurafenib (Zelboraf):銷售額預測
  • 其他黑色素瘤激化酵素抑制劑的市場
    • 其他激化酵素抑制劑:銷售額預測

第5章 黑色素瘤的免疫療法藥:全球市場分析與預測

  • 全球黑色素瘤免疫療法藥市場現在
    • 黑色素瘤免疫療法藥:全球市場的預測
    • 黑色素瘤免疫療法藥:主要產品的佔有率的變化預測
  • Ipilimumab (Yervoy):Bristol Myers Squib
    • Ipilimumab (Yervoy):過去的銷售情況
    • Ipilimumab (Yervoy):銷售額預測
  • PegIntron (Peginterferon Alpha-2b; Sylatron, IntronA):Merck
    • PegIntron:過去的銷售情況
    • PegIntron:銷售額預測
  • Proleukin (Aldesleukin):Prometheus/Novartis
    • Proleukin (Aldesleukin):過去的銷售情況
    • Proleukin (Aldesleukin):銷售額預測
  • Keytruda (Pembrolizumab):Merck
    • Keytruda相關專利訴訟
    • Keytruda (Pembrolizumab):銷售額預測
  • 黑色素瘤的其他免疫療法藥的市場
    • 其他免疫療法藥:銷售額預測

第6章 黑色素瘤的化療劑:全球市場分析與預測

  • 全球黑色素瘤化療劑市場現在
    • 黑色素瘤化療劑:全球市場的預測
  • Dacarbazine (DTIC-Dome):Bayer
    • Dacarbazine的潛在的聯合治療
  • Temodar/Temodal (Temozolomide):Merck
    • Temodar/Temodal (Temozolomide):過去的銷售情況
    • Temodar/Temodal (Temozolomide):銷售額預測
  • 其他黑色素瘤化療劑
    • Cisplatin (Platinol)
    • Fotemustine
    • Bleomycin (Blenoxane)
    • 其他的化學療法劑:銷售額預測

第7章 主要國家市場預測

  • 黑色素瘤治療藥市場:各地區
    • 黑色素瘤治療藥的全球分佈
  • 主要國家市場預測
    • 各地區佔有率的變化預測
  • 地區市場:分析與預測
  • 美國:最大規模的市場
    • 美國市場:市場預測
  • 歐盟5國市場
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
  • 澳洲
  • 日本
  • 中國
  • 印度
  • 巴西
  • 土耳其
  • 俄羅斯
  • 全球其他的地區

第8章 主要企業

  • 黑色素瘤治療藥市場:動態的市場
  • Bayer AG
    • 藥物組合
    • 開發平台
  • Bristol Myers Squib
    • 癌症治療藥組合
    • 癌症治療藥開發平台
  • GlaxoSmithKline (GSK)
    • 癌症治療藥組合
    • 癌症治療藥開發平台
  • Merck
    • 癌症治療藥組合
    • 癌症治療藥開發平台
  • Prometheus Laboratories
    • 癌症治療藥組合
    • 癌症治療藥開發平台
  • Roche
    • 癌症治療藥組合
    • 癌症治療藥開發平台

第9章 黑色素瘤治療藥:研究開發藥物候補

  • 開發平台:黑色素瘤激化酵素抑制劑
    • Binimetinib (MEK162):Novartis
    • Cobimetinib-Exelixis/Roche
    • Encorafenib (LGX818):Novartis
    • Tasigna (Nilotinib):Novartis
  • 開發平台:黑色素瘤免疫療法藥
    • Genasense (Oblimersen Sodium):Genta Incorporated
    • INCB024360:Incyte Corporation
    • MEDI4736/MedImmune
    • MPDL3280A:Roche/Genentech
    • Nivolumab (Opdivo):Bristol Myers Squibb/小野藥品工業
  • 開發平台:黑色素瘤疫苗
    • Astuprotimut-R (MAGE-A3 ASCI):GlaxoSmithKline
    • CDX-1401:Celldex Therapeutics
    • Talimogene Laherparepvec (T-Vec):Amgen
  • 開發平台:黑色素瘤基因治療藥
    • Allovectin-7 (Velimogene Aliplasmid):Vical Incorporated
    • Dorgenmeltucel-L:NewLink Genetics Corporation
  • 開發平台:黑色素瘤的其他的治療藥物
    • Abraxane:Celgene Corporation
    • Autologous Dendritic Cell-Tumour Cell Immunotherapy:NeoStem

第10章 全球黑色素瘤治療藥市場:定性分析

  • 市場影響因素
  • SWOT分析
  • 波特的五力分析分析

第11章 專家的見解

  • Jean-Pierre Bizzari博士(Global Head Of Oncology, Celgene Corporation)
  • Rosalie M. Luiten博士(PhD, Head of the Laboratory of Experimental Dermatology, Dept of Dermatology, Academic Medical Center, University of Amsterdam)

第12章 總論

圖表清單

目錄
Product Code: PHA0012

Melanoma Drugs - new study showing you trends, R&D progress, and predicted revenues

Where is the melanoma drugs market heading What are the commercial prospects for this market and related technologies Visiongain's new report shows you potential revenues and other trends to 2024, discussing data, opportunities and prospects.

Our new 215 page report provides 185 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at world market, submarket and national level. You will see financial results, interviews, trends, opportunities and revenue predictions.

Forecasts from 2014-2024 and other analyses show you commercial prospects

Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter's Five Forces), company profiles and commercial developments. Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:

  • Dr Jean-Pierre Bizzari, Global Head of Oncology, Celgene Corporation
  • Dr Rosalie M. Luiten, Head of the Laboratory of Experimental Dermatology, Dept of Dermatology, Academic Medical Center, University of Amsterdam

You find prospects for key submarkets

In addition to analyses of the overall world market, you see revenue forecasts for these four submarkets to 2024:

  • Chemotherapeutic melanoma drugs
  • Kinase Inhibitors
  • Immunotherapeutic melanoma drugs
  • Other melanoma drugs

Drugs that can significantly increase disease-free and progression-free survival while also improving patient tolerance will achieve success. Combination therapies aimed at attacking melanoma from multiple angles will prove successful in providing added benefits to patients and manufacturers.

Our investigation shows business research and analyses with individual revenue forecasts and discussions. You find the dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for products

How will leading drugs perform to 2024 at the world level How will promising products currently in the pipeline perform once they are launched Our study forecasts sales of 14 melanoma products including these:

  • Dabrafenib (Tafinlar)
  • Trametinib (Mekinist)
  • Vemurafenib (Zelboraf)
  • Ipilimumab (Yervoy)
  • PegIntron (Sylatron)
  • Proleukin (Aldesleukin)
  • Pembrolizumab (Keytruda)
  • Binimetinib
  • Cobimetinib
  • Tasigna
  • Temodar
  • Nivolumab
  • T-Vec
  • Abraxane

Discover how high revenues can go. You will see what is happening, understanding trends, challenges and opportunities.

What are the prospects for the leading regions and countries

In addition to analyses of the overall world market, you discover individual revenue forecasts for 13 national markets to 2024:

  • US
  • Australia
  • Japan
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Brazil
  • Russia
  • India
  • China
  • Turkey
  • Rest of the World

Our analyses show sustained growth, particularly for the markets with high predisposition factors to melanoma such as in Australia, Europe, and the Americas. New product approvals and the development of innovative targeted therapies will influence market growth.

Regulatory, demographic, and commercial developments worldwide will influence the markets both in the established North American and Western European economies, and the fast-rising emerging markets.

Leading companies and potential for market growth

Overall world revenue for melanoma drugs will reach $2bn in 2014, our work forecasts. Rising demand for melanoma drugs, expanding healthcare coverage, recently launched therapies and a strong R&D pipeline will increase sales to 2024.

Our work shows you what organisations hold greatest potential. See profiles of 6 leading companies, including these:

  • Bayer AG
  • Bristol Myers Squibb
  • GSK
  • Merck
  • Prometheus Laboratories
  • Roche

A company profile gives you the following information:

  • Recent financial results
  • Discussions of a company's activities and outlook, including oncology product portfolios and pipelines
  • Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures.

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

Research and development activities

What is happening in the R&D pipeline for melanoma drugs You see developmental trends, gaining insight into the R&D pipeline for:

  • Kinase inhibitors for melanoma
  • Immunotherapeutic agents for melanoma
  • Vaccines for melanoma
  • Genetic therapies for melanoma
  • Other therapies for melanoma treatment

What issues will affect the melanoma drugs market

Our new report discusses issues and events affecting the melanoma drugs market. You will find discussions of many issues and developments, including:

  • Reimbursement, regulations, patent expiries, generic competition
  • Cost savings and efficiencies
  • The use of biologics, targeted and combination therapies
  • Understanding melanoma aetiology and progression
  • Safety and patient compliance
  • Clinical evidence supporting product efficacy

Our investigation gives you multi-level business research and analyses with sales forecasts. You see how that industry and market can perform from 2014 to 2024.

How the Melanoma Drugs Market Forecast 2014-2024: Opportunities for Leading Companies report helps you

In summary our 215 page report gives you the following knowledge:

  • Revenue forecasts to 2024 for the overall melanoma drugs market and 4 submarkets - discover the industry's prospects, finding promising areas for investments and revenues
  • Predicted revenues for 14 melanoma drugs - discover prospects for leading products in the market and promising therapies in the pipeline, with forecasted revenues provided to 2024
  • Revenue forecast to 2024 for 13 leading national markets - US, Japan, Germany, France, the UK, Italy, Spain, Australia, Brazil, Russia, India, China, Turkey, and Rest of the World
  • Evaluation of pipeline drugs - find the market potential for leading products currently in the development pipeline in each market segment
  • Assessment of 6 leading companies - hear about products, results and strategies, including recent activities and outlook for companies such as Merck, Novartis, GSK, Bristol Myers Squibb, and Roche
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market
  • Opinions from our survey, seeing interviews with industry authorities

You will find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for melanoma drugs. You will find data, trends and predictions. Please order our report now.

Table of Contents

1. Report Overview

  • 1.1 Global Melanoma Drugs: Market Overview
  • 1.2 Global Melanoma Drugs Market Segmentation
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered By This Analytical Report
  • 1.6 Who Is This Report For
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Reports
  • 1.10 About Visiongain

2. An Introduction to Cancer, Melanoma, and Melanoma Treatments

  • 2.1 Cancer: Physiology, Causes, And Effects
    • 2.1.1 Uncontrolled Growth
    • 2.1.2 Dedifferentiation
    • 2.1.3 Invasiveness And Metastasis
    • 2.1.4 Causes Of Cancer
  • 2.2 Melanoma: A Brief Introduction
    • 2.2.1 Causes Of Melanoma
    • 2.2.2 Symptoms And Appearances Of Melanoma
  • 2.3 Stages Of Melanoma
    • 2.3.1 Early Stage Melanoma
    • 2.3.2 Medium Stage Melanoma
    • 2.3.3 Advanced Melanoma
  • 2.4 The Incidence and Outlook for Melanoma - Global Trends
  • 2.5 Surgery As A Treatment For Melanoma
  • 2.6 The Use Of Radiotherapy In Melanoma Treatment
  • 2.7 Drug Treatments In Melanoma
    • 2.7.1 Traditional Chemotherapy
    • 2.7.2 Immunotherapy
      • 2.7.2.1 Monoclonal Antibodies (mAbs)
      • 2.7.2.2 Cancer Vaccines
      • 2.7.2.3 Non-Specific Immunotherapies
  • 2.8 Market Definition

3. World Melanoma Drugs Market, 2014-2024

  • 3.1 Global Melanoma Drugs: Market Overview
    • 3.1.1 Categorisation Of The Global Melanoma Drugs Market
  • 3.2 The Global Melanoma Market In 2013
    • 3.2.1 Market Dominance Of Immunotherapeutic Drugs And Targeted Therapies
  • 3.3 Global Melanoma Drugs: Market Forecast 2014-2024
    • 3.3.1 Market Sectors That Will Drive Growth
    • 3.3.2 Global Melanoma Drugs Market - Changing Market Shares By Sector 2014-2024

4. Kinase Inhibitors For Melanoma: World Market Analysis and Forecast, 2014-2024

  • 4.1 The Global Market For Melanoma Kinase Inhibitors, 2013
    • 4.1.1 Melanoma Kinase Inhibitors: Global Market Forecast 2014-2024
    • 4.1.2 Melanoma Kinase Inhibitors - Changing Market Shares By Leading Drugs 2014-2024
  • 4.2 Dabrafenib (Tafinlar) - GlaxoSmithKline
    • 4.2.1 Dabrafenib (Tafinlar) - Sales Forecast, 2014-2024
  • 4.3 Trametinib (Mekinist) - GlaxoSmithKline
    • 4.3.1 Trametinib (Mekinist) - Sales Forecast 2014-2024
  • 4.4 Vemurafenib (Zelboraf) - Roche/ Genentech/ Chugai/ Daiichi Sankyo
    • 4.4.1 Vemurafenib (Zelboraf) - Historical Sales Analysis, 2011-2013
    • 4.4.2 Vemurafenib (Zelboraf) - Sales Forecast 2014-2024
  • 4.5 The Market For Other Kinase Inhibitors In Melanoma
    • 4.5.1 Other Kinase Inhibitors - Sales Forecast 2014-2024

5. Immunotherapeutic Agents For Melanoma: World Market Analysis and Forecast, 2014-2024

  • 5.1 The Global Market For Immunotherapeutic Agents In Melanoma, 2013
    • 5.1.1 Melanoma Immunotherapeutic Agents: Global Market Forecast 2014-2024
    • 5.1.2 Melanoma Immunotherapeutic Agents - Changing Market Shares By Leading Drugs 2014-2024
  • 5.2 Ipilimumab (Yervoy) - Bristol Myers Squibb
    • 5.2.1 Ipilimumab (Yervoy) - Historical Sales Analysis, 2011-2013
    • 5.2.2 Ipilimumab (Yervoy) - Sales Forecast 2014-2024
  • 5.3 PegIntron (Peginterferon Alpha-2b; Sylatron, IntronA) - Merck
    • 5.3.1 PegIntron - Historical Sales Analysis, 2011-2013
    • 5.3.2 PegIntron - Sales Forecast 2014-2024
  • 5.4 Proleukin (Aldesleukin) - Prometheus Laboratories/ Novartis
    • 5.4.1 Proleukin (Aldesleukin) - Historical Sales Analysis, 2011-2013
    • 5.4.2 Proleukin (Aldesleukin) - Sales Forecast 2014-2024
  • 5.5 Keytruda (Pembrolizumab) - Merck
    • 5.5.1 Patent Disputes Over Keytruda
    • 5.5.2 Keytruda (Pembrolizumab) - Sales Forecast 2014-2024
  • 5.6 The Market For Other Immunotherapeutic Agents In Melanoma
    • 5.6.1 Other Immunotherapeutic Agents - Sales Forecast 2014-2024

6. Chemotherapeutic Agents For Melanoma: World Market Analysis and Forecast, 2014-2024

  • 6.1 The Global Market For Melanoma Chemotherapeutic Agents, 2013
    • 6.1.1 Melanoma Chemotherapeutic Agents: Global Market Forecast 2014-2024
  • 6.2 Dacarbazine (DTIC-Dome) - Bayer
    • 6.2.1 Possible Combination Therapies Involving Dacarbazine
  • 6.3 Temodar/Temodal (Temozolomide) - Merck
    • 6.3.1 Temodar/Temodal (Temozolomide) - Historical Sales Analysis, 2011-2013
    • 6.3.2 Temodar/Temodal (Temozolomide) - Sales Forecast 2014-2024
  • 6.4 Other Chemotherapeutic Agents In Melanoma Treatment
    • 6.4.1 Cisplatin (Platinol)
      • 6.4.1.1 Cisplatin (Platinol) - Historical Sales Analysis, 2010-2012
    • 6.4.2 Fotemustine
    • 6.4.3 Bleomycin (Blenoxane)
    • 6.4.4 Other Chemotherapeutic Agents - Sales Forecast 2014-2024

7. Leading National Markets for Melanoma Drugs, 2014-2024

  • 7.1 The Melanoma Drugs Market By Region
    • 7.1.1 The Global Distribution of Melanoma Drugs In 2013
  • 7.2 Leading National Markets: Forecast 2014-2024
    • 7.2.1 Changing Market Shares By Region, 2014-2024
  • 7.3 Regional Melanoma Drugs Markets: Analysis And Forecasts, 2014-2024
  • 7.4 United States: The Largest Melanoma Drug Market
    • 7.4.1 US Melanoma Drugs Market: Market Forecast 2014-2024
  • 7.5 The EU5 Markets: Growth Expected In Each Country
    • 7.5.1 EU5 Melanoma Drugs Market: Market Forecast 2014-2024
      • 7.5.1.1 EU5 Markets: Changing Market Shares By Country, 2014-2024
    • 7.5.2 Germany: New Reforms To Medicinal Pricing May Impact Market Entry
      • 7.5.2.1 German Melanoma Drugs Market: Market Forecast 2014-2024
    • 7.5.3 France: Changing Drug Approval Process May Delay Regulatory Submissions
      • 7.5.3.1 French Melanoma Drugs Market: Market Forecast 2014-2024
    • 7.5.4 UK: Cost-Effectiveness Measures Impacting Growth
      • 7.5.4.1 UK Melanoma Drugs Market: Market Forecast 2014-2024
    • 7.5.5 Italy: Economic Recovery To Boost Future Of Oncology
      • 7.5.5.1 Italian Melanoma Drugs Market: Market Forecast 2014-2024
    • 7.5.6 Spain: High Level Of Patient Needs Will Counter Healthcare Rationalisation Measures
      • 7.5.6.1 Spain Melanoma Drugs Market: Market Forecast 2014-2024
  • 7.6 Australia: Highest Melanoma Incidence Rate Globally
    • 7.6.1 Australian Melanoma Drugs Market: Market Forecast 2014-2024
  • 7.7 Japan: Openness To Innovation Will Drive Revenue Increase
    • 7.7.1 Japanese Melanoma Drugs Market: Market Forecast 2014-2024
  • 7.8 China: Heavy Reliance On Traditional Herbal Remedies
    • 7.8.1 Chinese Melanoma Drugs Market: Market Forecast 2014-2024
  • 7.9 India: Contrasting Effects Of A Growing Population And Weak IP Protection
    • 7.9.1 Indian Melanoma Drugs Market: Market Forecast 2014-2024
  • 7.10 Brazil: Political Mandates And Economic Development Will Stimulate Growth
    • 7.10.1 Brazilian Melanoma Drugs Market: Market Forecast 2014-2024
  • 7.11 Turkey: Population Growth And Migration Will Be Tools For Growth
    • 7.11.1 Turkish Melanoma Drugs Market: Market Forecast 2014-2024
  • 7.12 Russia: High Income Nation With Low Per-Capita Healthcare Spending
    • 7.12.1 Russian Melanoma Drugs Market: Market Forecast 2014-2024
  • 7.13 Rest of the World
    • 7.13.1 Rest of the World Melanoma Drugs Market: Market Forecast 2014-2024

8. Leading Companies In The Melanoma Drugs Market, 2014

  • 8.1 Melanoma Drugs Market: A Highly Dynamic Market Space
  • 8.2 Bayer AG
    • 8.2.1 Bayer Oncology Drug Portfolio, 2014
    • 8.2.2 Bayer Oncology Drug Pipeline, 2014
  • 8.3 Bristol Myers Squibb
    • 8.3.1 Bristol Myers Squibb: Oncology Drug Portfolio, 2014
    • 8.3.2 Bristol Myers Squibb: Oncology Development Pipeline, 2014
  • 8.4 GlaxoSmithKline (GSK)
    • 8.4.1 GSK: Oncology Drug Portfolio, 2014
    • 8.4.2 GSK: Oncology Development Pipeline, 2014
    • 8.4.3 GSK Asset Swap with Novartis to Restructure Consumer Health
  • 8.5 Merck
    • 8.5.1 Merck: Oncology Drugs Portfolio, 2014
    • 8.5.2 Merck: Oncology Development Pipeline, 2014
  • 8.6 Prometheus Laboratories
    • 8.6.1 Prometheus Laboratories: Oncology Portfolio, 2014
  • 8.7 Roche
    • 8.7.1 Roche: Oncology Portfolio, 2014
    • 8.7.2 Roche: Oncology Development Pipeline, 2014

9. Melanoma Drugs: R&D Pipeline, 2014-2024

  • 9.1 Innovative Products Currently In Development Will Drive Growth
    • 9.1.1 Co-Developments And Collaborations Are Crucial For Market Growth
  • 9.2 Developmental Pipeline - Kinase Inhibitors For Melanoma, 2014
    • 9.2.1 Binimetinib (MEK162) - Novartis
      • 9.2.1.1 Binimetinib (MEK162) - Sales Forecast 2014-2024
    • 9.2.2 Cobimetinib - Exelixis /Genentech/ Roche
      • 9.2.2.1 Co-Development And Licensing Agreements For Cobimetinib
      • 9.2.2.2 Clinical Trials And Development Efforts For Cobimetinib
      • 9.2.2.3 Cobimetinib - Sales Forecast 2014-2024
    • 9.2.3 Encorafenib (LGX818) - Novartis
    • 9.2.4 Tasigna (Nilotinib) - Novartis
      • 9.2.4.1 Tasigna - Indications And Market Exclusivity
      • 9.2.4.2 Tasigna In Melanoma
      • 9.2.4.3 Tasigna (Nilotinib) - Sales Forecast 2014-2024
  • 9.3 Developmental Pipeline - Immunotherapeutic Agents In Melanoma, 2014
    • 9.3.1 Genasense (Oblimersen Sodium) - Genta Incorporated
    • 9.3.2 INCB024360 - Incyte Corporation
    • 9.3.3 MEDI4736 - AstraZeneca/ MedImmune
    • 9.3.4 MPDL3280A - Roche/Genentech
    • 9.3.5 Nivolumab (Opdivo) - Bristol Myers Squibb/ Ono Pharmaceutical
      • 9.3.5.1 Nivolumab (Opdivo) - Sales Forecast 2014-2024
  • 9.4 Developmental Pipeline - Vaccine Therapies In Melanoma, 2014
    • 9.4.1 Astuprotimut-R (MAGE-A3 ASCI) - GlaxoSmithKline
    • 9.4.1.1 Clinical Trials And Development Efforts For Astuprotimut
    • 9.4.2 CDX-1401 - Celldex Therapeutics
    • 9.4.3 Talimogene Laherparepvec (T-Vec) - Amgen
      • 9.4.3.1 Clinical Trials And Development Efforts For T-Vec
      • 9.4.3.2 Talimogene Laherparepvec (T-Vec) - Sales Forecast 2014-2024
  • 9.5 Developmental Pipeline - Genetic Therapies In Melanoma, 2014
    • 9.5.1 Allovectin-7 (Velimogene Aliplasmid) - Vical Incorporated
      • 9.5.1.1 Allovectin-7 - Trial Setbacks And Efficacy Issues
    • 9.5.2 Dorgenmeltucel-L - NewLink Genetics Corporation
      • 9.5.2.1 Clinical Trials And Development Efforts For Dorgenmeltucel-L
  • 9.6 Developmental Pipeline - Other Therapies In Melanoma, 2014
    • 9.6.1 Abraxane - Celgene Corporation
      • 9.6.1.1 Clinical Trials And Development Efforts For Abraxane
      • 9.6.1.2 Abraxane - Sales Forecast 2014-2024
    • 9.6.2 Autologous Dendritic Cell-Tumour Cell Immunotherapy - NeoStem

10. Qualitative Analysis for the Global Melanoma Drugs Market, 2014-2024

  • 10.1 Market Factors Influencing The Melanoma Drugs Market
  • 10.2 SWOT Analysis Of The Melanoma Drugs Market, 2014-2024
    • 10.2.1 Strengths
      • 10.2.1.1 Promising Pipeline Candidates Expected To Boost Product Choice And Competitiveness
      • 10.2.1.2 Stratifying Patients Offers Clinical and Commercial Benefits
      • 10.2.1.3 Improved Patient Compliance Offer Added Incentive For Growth
    • 10.2.2 Weaknesses
      • 10.2.2.1 Disease Recurrence And Low Disease Free Survival May Hinder Investments
      • 10.2.2.2 High Development Costs Making Break-Even A Bigger Challenge For Marketed Drugs
      • 10.2.2.3 The Complexity Of Melanoma's Aetiology
    • 10.2.3 Opportunities
      • 10.2.3.1 Rising Melanoma Incidence Amidst A Rising Global Population Will Stimulate Growth
      • 10.2.3.2 A Shift Towards Personalisation
      • 10.2.3.3 Combination Therapies Bring Additive Benefits
      • 10.2.3.4 Commercial Success Leveraged By Clinical Benefit
    • 10.2.4 Threats
      • 10.2.4.1 Inadequate Reimbursement Levels: Drug Pricing Creating Constraints On Market Growth
      • 10.2.4.2 Melanoma Drugs Face The Prospect Of Generic Erosion Over Time
  • 10.3 Porter's Five Force Analysis Of The Melanoma Drugs Market, 2014-2024
    • 10.3.1 Threat Of New Entrants: Medium
    • 10.3.2 Threat Of Substitutes: Low
    • 10.3.3 Power Of Suppliers: Medium
    • 10.3.4 Power Of Buyers: Low
    • 10.3.5 Rivalry Among Competitors: Medium

11. Expert Opinions from Our Primary Research

  • 11.1 Interview With Dr Jean-Pierre Bizzari, Global Head Of Oncology, Celgene Corporation
    • 11.1.1 Targeted Therapies And Immune Checkpoints Are Areas For Accelerated Development
    • 11.1.2 The Economic Implications Of Patient Segmentation And Targeted Therapies
    • 11.1.3 On The Possible Combination Between Celgene's Abraxane And Bristol Myers Squibb's Nivolumab
    • 11.1.4 On Celgene's Strategy For Success In Oncology
    • 11.1.5 On The Current Challenges In Oncology And The Possible Solutions To Be Implemented
    • 11.1.6 On Work Being Done to Map Signalling Pathways And Exploit Cellular Mechanisms For Drug Development
    • 11.1.7 The Future Impact Of Regulatory Hurdles and Trial Design On Survival Advantage
  • 11.2 Interview With Dr Rosalie M. Luiten PhD, Head of the Laboratory of Experimental Dermatology, Dept of Dermatology, Academic Medical Center, University of Amsterdam
    • 11.2.1 Stages Of Melanoma And The Currently Available Treatment Options
    • 11.2.2 Recent Developments In Targeted Therapies For Melanoma
    • 11.2.3 Combination Therapies And The Challenge To Increase Durable Response Rate
    • 11.2.4 On The Current Treatment Options For Early Stage Melanoma
    • 11.2.5 On The Rising Popularity Of Immune Checkpoint Blockade In Oncology
    • 11.2.6 Monobenzone Therapy And Its Potential Use As A Melanoma Therapy
    • 11.2.7 On The Interactions Between Monobenzone And Immune Activating Compounds
    • 11.2.8 Future Plans For Monobenzone Therapy As A Melanoma Treatment
    • 11.2.9 On The Link Between Vitiligo And Melanoma
    • 11.2.10 On The Future Trend Of 'Per-Patient' Treatment Approaches To Melanoma

12. Conclusions

  • 12.1 Overview Of Current Market Conditions And Market Forecast, 2013-2024
  • 12.2 The US To Remain As The Largest Market
  • 12.3 Australia And Evolving Markets In Countries Such As Brazil And Turkey Will Stimulate Growth
  • 12.4 Personalisation And Targeted Treatments Will Dominate
  • 12.5 Strong Development Pipeline Will Be Crucial To Future Growth

List of Tables

  • Table 1.1 US Melanoma Incidence and Mortality: Breakdown by Age-Group (%), 2007-2011
  • Table 1.2 Redacted German Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 1.3 Redacted Global Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2013-2024
  • Table 2.1 The Clark Scale For Grading Melanoma, 2014
  • Table 2.2 Cancer-Treating Agents: Chemotherapies and Hormone Therapies, 2014
  • Table 2.3 Cancer-Treating Agents: Immunotherapies and Targeted Therapies, 2014
  • Table 3.1 The Global Melanoma Drugs Market: Revenue ($m) and Market Shares (%) by Sector, 2013
  • Table 3.2 The Global Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2013-2024
  • Table 3.3 The Global Melanoma Drugs Market Forecast: CAGR (%) by Sector, 2013-2018, 2018-2024, 2013-2024
  • Table 3.4 The Global Melanoma Drugs Market: Revenue ($m) by Sector, 2013, 2018, 2024
  • Table 3.5 The Global Melanoma Drugs Market: Market Share (%) by Sector, 2013, 2018, 2024
  • Table 4.1 The Global Market for Melanoma Kinase Inhibitors: Revenue ($m) and Market Shares (%) For Leading Drugs, 2013
  • Table 4.2 Global Melanoma Kinase Inhibitors: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2013-2024
  • Table 4.3 The Global Melanoma Kinase Inhibitors Market: Revenue ($m) by Leading Drugs, 2013, 2018, 2024
  • Table 4.4 The Global Melanoma Kinase Inhibitors Market: Market Share (%) by Leading Drugs, 2013, 2018, 2024
  • Table 4.5 Dabrafenib (Tafinlar): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 4.6 Trametinib (Mekinist): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 4.7 Vemurafenib (Zelboraf): Historical Sales ($m, AGR%), 2011-2013
  • Table 4.8 Vemurafenib (Zelboraf): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 4.9 Other Kinase Inhibitors Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 5.1 The Global Market for Melanoma Immunotherapeutic Agents: Revenue ($m) and Market Shares (%) by Leading Drugs, 2013
  • Table 5.2 Global Melanoma Immunotherapeutic Agents: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2013-2024
  • Table 5.3 The Global Melanoma Immunotherapeutic Agents Market: Revenue ($m) by Leading Drugs, 2013, 2018, 2024
  • Table 5.4 The Global Melanoma Immunotherapeutic Agents Market: Market Share (%) by Leading Drugs, 2013, 2018, 2024
  • Table 5.5 Ipilimumab (Yervoy): Historical Sales ($m, AGR%), 2011-2013
  • Table 5.6 Ipilimumab (Yervoy): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 5.7 PegIntron (Sylatron): Historical Sales ($m, AGR%), 2011-2013
  • Table 5.8 PegIntron (Sylatron): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 5.9 Proleukin (Aldesleukin): Historical Sales ($m, AGR%), 2011-2013
  • Table 5.10 Proleukin (Aldesleukin): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 5.11 Keytruda (Pembrolizumab): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 5.12 Other Immunotherapeutic Agents: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 6.1 The Global Market for Melanoma Chemotherapeutic Agents: Revenue ($m) and Market Shares (%) by Leading Drugs, 2013
  • Table 6.2 Global Melanoma Chemotherapeutic Agents: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2013-2024
  • Table 6.3 Temodar/Temodal (Temozolomide): Historical Sales ($m, AGR%), 2011-2013
  • Table 6.4 Temodar/Temodal (Temozolomide): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 6.5 Cisplatin (Paraplatin): Historical Sales ($m, AGR%), 2010-2012
  • Table 6.6 Other Chemotherapeutic Agents: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 7.1 The Global Melanoma Drugs Market: Market Size ($m) and Market Share (%) by Region, 2013
  • Table 7.2 Global Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2013-2024
  • Table 7.3 The Global Melanoma Drugs Market Forecast: CAGR (%) by Region, 2013-2018, 2018-2024, and 2013-2024
  • Table 7.4 The Global Melanoma Drugs Market Forecast: Market Share (%) by Region, 2013, 2018, and 2024
  • Table 7.5 US Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 7.6 US Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 7.7 EU5 Melanoma Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2013-2024
  • Table 7.8 The EU5 Melanoma Drugs Market: Revenue ($m) and Market Share (%) by Country, 2013
  • Table 7.9 EU5 Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 7.10 The EU5 Melanoma Drugs Market: Market Share (%) by Country, 2013, 2018, 2024
  • Table 7.11 The German Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 7.12 The German Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 7.13 The French Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 7.14 The French Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 7.15 The UK Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 7.16 The UK Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 7.17 The Italian Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 7.18 The Italian Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 7.19 The Spanish Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 7.20 The Spanish Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 7.21 The Australian Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 7.22 The Australian Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 7.23 The Japanese Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 7.24 The Japanese Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 7.25 The Chinese Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 7.26 The Chinese Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 7.27 The Indian Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 7.28 The Indian Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 7.29 The Brazilian Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 7.30 The Brazilian Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 7.31 The Turkish Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 7.32 The Turkish Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 7.33 The Russian Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
  • Table 7.34 The Russian Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 7.35 The Rest of the World Melanoma Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2013-2024
  • Table 7.36 The Rest of the World Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 8.1 Bayer: Overview, 2014
  • Table 8.2 Bayer: Oncology Portfolio, 2014
  • Table 8.3 Bayer: Oncology Development Pipeline, 2014
  • Table 8.4 Bristol Myers Squibb (BMS): Overview, 2014
  • Table 8.5 Bristol Myers Squibb: Oncology Portfolio, 2014
  • Table 8.6 Bristol Myers Squibb: Oncology Development Pipeline, 2014
  • Table 8.7 GlaxoSmithKline (GSK): Overview, 2014
  • Table 8.8 GlaxoSmithKline (GSK): Oncology Portfolio, 2014
  • Table 8.9 GlaxoSmithKline (GSK): Oncology Pipeline, 2014
  • Table 8.10 Merck: Overview, 2014
  • Table 8.11 Merck: Oncology Portfolio, 2014
  • Table 8.12 Merck: Oncology Pipeline, 2014
  • Table 8.13 Prometheus Laboratories: Overview, 2014
  • Table 8.14 Prometheus Laboratories: Drug Portfolio, 2014
  • Table 8.15 Roche: Overview, 2014
  • Table 8.16 Roche: Oncology Portfolio, 2014
  • Table 8.17 Roche: Oncology Pipeline, 2014
  • Table 9.1 R&D Pipeline For Kinase Inhibitors In Melanoma, 2014
  • Table 9.2 Binimetinib (MEK162): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 9.3 Cobimetinib: Potential Combination Therapies, 2014
  • Table 9.4 Cobimetinib: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 9.5 Tasigna (Nilotinib): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 9.6 R&D Pipeline For Immunotherapeutic Agents In Melanoma, 2014
  • Table 9.7 Nivolumab (Opdivo): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 9.8 R&D Pipeline For Vaccine Therapies In Melanoma, 2014
  • Table 9.9 Talimogene Laherparepvec (T-Vec): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 9.10 R&D Pipeline For Genetic Therapies In Melanoma, 2014
  • Table 9.11 R&D Pipeline For Other Therapies In Melanoma Treatment, 2014
  • Table 9.12 Abraxane: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
  • Table 10.1 Melanoma Drugs: Market Drivers and Restraints 2014-2024
  • Table 10.2 SWOT Analysis of the Melanoma Drugs Market, 2014-2024
  • Table 12.1 Global Melanoma Drugs: Market Forecast ($m, CAGR%), 2013, 2018, 2021, 2024
  • Table 12.2 Global Melanoma Drugs: Market Shares (%) by Region, 2013, 2018, 2021, 2024
  • Table 12.3 Global Melanoma Drugs: Market Forecast ($m) by Sector, 2013, 2018, 2021, 2024

List of Figures

  • Figure 1.1 US Melanoma Incidence and Mortality: Breakdown by Age-Group (%), 2007-2011
  • Figure 1.2 Global Melanoma Drugs Market: Submarkets, 2014
  • Figure 3.1 The Global Melanoma Drugs Market: Revenue ($m) by Sector, 2013
  • Figure 3.2 The Global Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 3.3 The Global Melanoma Drugs Market Forecast: CAGR (%) by Sector, 2013-2018
  • Figure 3.4 The Global Melanoma Drugs Market Forecast: CAGR (%) by Sector, 2018-2024
  • Figure 3.5 The Global Melanoma Drugs Market Forecast: CAGR (%) by Sector, 2013-2024
  • Figure 3.6 The Global Melanoma Drugs Market: Revenue ($m) by Sector, 2013, 2018, 2024
  • Figure 3.7 The Global Melanoma Drugs Market: Market Share (%) by Sector, 2013
  • Figure 3.8 The Global Melanoma Drugs Market: Market Share (%) by Sector, 2018
  • Figure 3.9 The Global Melanoma Drugs Market: Market Share (%) by Sector, 2024
  • Figure 4.1 The Global Market for Melanoma Kinase Inhibitors: Revenue ($m) For Leading Drugs, 2013
  • Figure 4.2 Global Melanoma Kinase Inhibitors: Market Forecast ($m, AGR%), 2013-2024
  • Figure 4.3 The Global Melanoma Kinase Inhibitors Market: Market Share (%) by Leading Drugs, 2013
  • Figure 4.4 The Global Melanoma Kinase Inhibitors Market: Market Share (%) by Leading Drugs, 2018
  • Figure 4.5 The Global Melanoma Kinase Inhibitors Market: Market Share (%) by Leading Drugs, 2024
  • Figure 4.6 Dabrafenib (Tafinlar): Sales Forecast ($m, AGR%), 2013-2024
  • Figure 4.7 Trametinib (Mekinist): Sales Forecast ($m, AGR%), 2013-2024
  • Figure 4.8 Vemurafenib (Zelboraf): Historical Sales ($m, AGR%), 2011-2013
  • Figure 4.9 Vemurafenib (Zelboraf): Sales Forecast ($m, AGR%), 2013-2024
  • Figure 4.10 Other Kinase Inhibitors: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 5.1 The Global Market for Melanoma Immunotherapeutic Agents: Revenue ($m) by Leading Drugs, 2013
  • Figure 5.2 Global Melanoma Immunotherapeutic Agents: Market Forecast ($m, AGR%), 2013-2024
  • Figure 5.3 The Global Melanoma Immunotherapeutic Agents Market: Market Share (%) by Leading Drugs, 2013
  • Figure 5.4 The Global Melanoma Immunotherapeutic Agents Market: Market Share (%) by Leading Drugs, 2018
  • Figure 5.5 The Global Melanoma Immunotherapeutic Agents Market: Market Share (%) by Leading Drugs, 2024
  • Figure 5.6 Ipilimumab (Yervoy): Historical Sales ($m, AGR%), 2011-2013
  • Figure 5.7 Ipilimumab (Yervoy): Sales Forecast ($m, AGR%), 2013-2024
  • Figure 5.8 PegIntron (Sylatron): Historical Sales ($m, AGR%), 2011-2013
  • Figure 5.9 PegIntron (Sylatron): Sales Forecast ($m, AGR%), 2013-2024
  • Figure 5.10 Proleukin (Aldesleukin): Historical Sales ($m, AGR%), 2011-2013
  • Figure 5.11 Proleukin (Aldesleukin): Sales Forecast ($m, AGR%), 2013-2024
  • Figure 5.12 Keytruda (Pembrolizumab): Sales Forecast ($m, AGR%), 2013-2024
  • Figure 5.13 Other Immunotherapeutic Agents: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 6.1 The Global Market for Melanoma Chemotherapeutic Agents: Revenue ($m) by Leading Drugs, 2013
  • Figure 6.2 Global Melanoma Chemotherapeutic Agents: Market Forecast ($m, AGR%), 2013-2024
  • Figure 6.3 Temodar/Temodal (Temozolomide): Historical Sales ($m, AGR%), 2011-2013
  • Figure 6.4 Temodar/Temodal (Temozolomide): Sales Forecast ($m, AGR%), 2013-2024
  • Figure 6.5 Cisplatin (Paraplatin): Historical Sales ($m, AGR%), 2010-2012
  • Figure 6.6 Other Chemotherapeutic Agents: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 7.1 The Global Melanoma Drugs Market: Market Size ($m) by Region, 2013
  • Figure 7.2 US, EU5, Japan, and Australia Melanoma Drugs Market: Market Forecast ($m), 2013-2024
  • Figure 7.3 Brazil, Russia, India, China, and Turkey Melanoma Drugs Market: Market Forecast ($m), 2013-2024
  • Figure 7.4 The Global Melanoma Drugs Market Forecast: CAGR (%) by Region, 2013-2018
  • Figure 7.5 The Global Melanoma Drugs Market Forecast: CAGR (%) by Region, 2018-2024
  • Figure 7.6 The Global Melanoma Drugs Market Forecast: CAGR (%) by Region, 2013-2024
  • Figure 7.7 The Global Melanoma Drugs Market Forecast: Market Share (%) by Region, 2013
  • Figure 7.8 The Global Melanoma Drugs Market Forecast: Market Share (%) by Region, 2018
  • Figure 7.9 The Global Melanoma Drugs Market Forecast: Market Share (%) by Region, 2024
  • Figure 7.10 US Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 7.11 The EU5 Melanoma Drugs Market: Revenues ($m) by Country, 2013
  • Figure 7.12 Germany, France, UK, Italy, and Spain Melanoma Drugs Market: Market Forecast ($m), 2013-2024
  • Figure 7.13 The EU5 Melanoma Drugs Market: Market Share (%) by Country, 2013
  • Figure 7.14 The EU5 Melanoma Drugs Market: Market Share (%) by Country, 2018
  • Figure 7.15 The EU5 Melanoma Drugs Market: Market Share (%) by Country, 2024
  • Figure 7.16 The German Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 7.17 The French Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 7.18 The UK Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 7.19 The Italian Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 7.20 The Spanish Melanoma Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 7.21 The Australian Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 7.22 The Japanese Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 7.23 The Chinese Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 7.24 The Indian Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 7.25 The Brazilian Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 7.26 The Turkish Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 7.27 The Russian Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 7.28 The Rest of the World Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
  • Figure 9.1 Binimetinib (MEK162): Sales Forecast ($m, AGR%), 2013-2024
  • Figure 9.2 Cobimetinib: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 9.3 Tasigna (Nilotinib): Sales Forecast ($m, AGR%), 2013-2024
  • Figure 9.4 Nivolumab (Opdivo): Sales Forecast ($m, AGR%), 2013-2024
  • Figure 9.5 Talimogene Laherparepvec (T-Vec): Sales Forecast ($m, AGR%), 2013-2024
  • Figure 9.6 Abraxane: Sales Forecast ($m, AGR%), 2013-2024
  • Figure 10.1 Porter's Five Force Analysis of the Melanoma Drugs Market, 2014
  • Figure 12.1 Global Melanoma Drugs: Market Forecast ($m), 2013, 2018, 2021, 2024
  • Figure 12.2 Top Selling Melanoma Drugs, 2013
  • Figure 12.3 Global Melanoma Drugs: Market Forecast ($m) by Sector, 2013-2024

Companies Listed

  • Abraxis BioScience
  • Adaptimmune
  • Algeta ASA
  • APP Pharmaceuticals
  • Amgen
  • AstraZeneca
  • Bayer
  • Bedford Laboratories (Hikma Pharmaceuticals)
  • Boehringer Ingelheim
  • BioVex Inc
  • Bristol Myers Squibb
  • Celgene Corporation
  • Chiron Corporation (Novartis)
  • Chugai
  • Daiichi Sankyo
  • Exelixis
  • Endocyte Inc
  • Genentech (Roche)
  • Genta Incorporated
  • GlaxoSmithKline
  • Incyte Corporation
  • JenaPharm (Bayer)
  • Ono Pharmaceutical
  • OncoMed Pharmaceutical
  • Onyx Pharmaceuticals
  • Mayne Pharma
  • Merck
  • Mylan Pharmaceuticals
  • NeoStem Inc
  • Nestle Health Sciences
  • NewLink Genetics Corporation
  • Novartis
  • Pfizer
  • Prometheus Laboratories
  • Roche
  • Steigerwald Arzneimittelwerk GmbH
  • Teva Pharmaceuticals
  • Zymogenetics

Organisations Mentioned In The Report

  • Academic Medical Center, University of Amsterdam
  • American Society of Clinical Oncology (ASCO)
  • American Society of Hematology (ASH)
  • CancerAustralia
  • Commision de la Transparence [France]
  • The National Cancer Institute (SEER) [US]
  • Food and Drugs Administration (FDA) [US]
  • European Organisation for the Research and Treatment of Cancer (EORTC)
  • European Medicines Agency (EMA)
  • European Society for Medical Oncology (ESMO)
  • Ludwig Institute for Cancer Research
  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (iQWiG) [Germany]
  • Ministry of Health Labour and Welfare (MHLW) [Japan]
  • National Institute for Health and Care Excellence (NICE) [UK]
  • Society for Immunotherapy of Cancer (SITC)
  • US Patent & Trademark Office
  • Therapeutic Goods Administration [Australia]
  • World Health Organisation (WHO)
  • World Cancer Research Fund International
  • World Trade Organisation
Back to Top